CytomX Therapeutics Inc CTMX:NASDAQ

Set AlertOptionsStreaming Charts
Last Price$1.62NASDAQ Previous Close - Last Trade as of 4:00PM ET 5/20/22
NASDAQ 15-minute delayed Bid/Ask Quotes
Today's Change0(0.00%)
Bid (Size)$1.53 (4)
Ask (Size)$1.75 (2)
Day Low / HighN/A - N/A
Volume648.4 K
Sell
Buy

FDA Clears CytomX's Investigational New Drug Application for CX-904 in Advanced Solid Tumors

9:02AM ET 1/19/2022 MT Newswires
CytomX Therapeutics (CTMX) said Wednesday the US Food and Drug Administration has cleared the investigational new drug application for CX-904 being co-developed by the company and Amgen (AMGN) for the treatment of advanced solid tumors.

According to the biopharmaceutical firm, CX-904 is the first T-cell-engaging bispecific antibody and the sixth therapeutic candidate from its Probody platform to enter clinical trial.

Shares rose 0.5% in premarket trading.

Price: 3.95, Change: +0.12, Percent Change: +3.13

Most Popular Keyword Searches

FNMA JCP amd MSFT TWTR Enter Symbol or Name ddd GPRO FB F GE amzn tsla spy znga BABA bac NFLX AAPL MJNA